Navigation Links
Selexys Pharmaceuticals Initiates Enrollment in Phase I Clinical Study of SelG1
Date:5/4/2011

OKLAHOMA CITY, May 4, 2011 /PRNewswire/ -- Selexys Pharmaceuticals announced today that it has initiated enrollment in a Phase I clinical study of its lead compound, SelG1, a humanized anti-P-selectin antibody.  

The placebo-controlled, double-blind, first-in-human, ascending single dose and multiple dose study of SelG1 will enroll approximately 30 healthy subjects. This study will evaluate the safety and pharmacology of SelG1 prior to advancement into a Phase II trial in patients with sickle cell disease.

"This Phase I study represents the first step in understanding the potential of SelG1 to address the unmet medical need in sickle cell disease and we are excited to initiate the clinical development of this novel compound," said Dr. Scott Rollins, Selexys President and CEO. "This Phase I trial represents a key milestone for Selexys as we transition from a preclinical to a clinical development stage biopharmaceutical company."

In 2008, Selexys received orphan-drug designation for SelG1 from the Food and Drug Administration Office of Orphan Products Development for the treatment of vasoocclusive crisis, a severe and painful complication of sickle cell disease. Orphan drug designation is awarded to therapeutics with the potential for safe and effective treatment diagnosis or prevention of rare diseases and disorders that affect fewer than 200,000 people.

About SelG1

SelG1 is an investigational humanized monoclonal antibody directed against P-selectin, a key member of the adhesion molecule family known as the selectins. In preclinical studies, inhibition of P-selectin has been shown to effectively prevent vasoocclusion by blocking critical cell-cell interactions that drive this process. Therapeutic blockade of P-selectin may therefore reduce vasoocclusion and subsequent crises in patients with sickle cell disease.

"SelG1 represents a first-in-class therapeutic approach for the treatment of sickle cell disease and potentially other proinflammatory and prothrombotic conditions," stated Dr. Russell Rother, who heads the clinical development program for Selexys. "Effective therapies that target vasoocclusion are needed to address the serious complications in patients with this life-threatening disease."

The SelG1 program for sickle cell disease is supported by a Small Business Innovation Research (SBIR) fast-track award #5R44HL093893-02 through the National Heart, Lung and Blood Institute.

About Selexys Pharmaceuticals

Selexys is a privately held biopharmaceutical company that is focused on development of therapeutics for the treatment of inflammation and thrombosis across a broad range of severe diseases. Selexys is also developing SelK1, a fully human monoclonal antibody directed against PSGL-1 for the treatment of Crohn's Disease and other inflammatory disorders. Selexys is headquartered in Oklahoma City, OK.  For additional information please visit our website at www.selexys.com.  


'/>"/>
SOURCE Selexys Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Aires Pharmaceuticals Appoints Edwin L. Parsley as Chief Medical Officer
2. Keryx Biopharmaceuticals, Inc. Prices Common Stock Offering
3. MHPA Center for Best Practices Receives Sponsorship from Ortho-McNeil Janssen Pharmaceuticals, Inc. to Improve Medicaid Quality, Care Coordination for Serious Mental Illness
4. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10
5. Auxilium Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
6. Onyx Pharmaceuticals Reports First Quarter 2011 Financial Results
7. Pacira Pharmaceuticals, Inc. Announces Timing for First Quarter 2011 Financial Results Webcast and Conference Call
8. Anthera Pharmaceuticals Reports 2011 First Quarter Financial Results and Operational Update
9. Jazz Pharmaceuticals Announces First Quarter 2011 Financial Results
10. Idenix Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
11. Isis Pharmaceuticals to Present at the 14th Annual Bank of America Merrill Lynch Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... YORK , Feb. 22, 2017 ... the myocardial infarction partnering deals and agreements entered ... Read the full report: http://www.reportlinker.com/p03605670-summary/view-report.html ... report provides understanding and access to partnering deals ... healthcare companies. - Trends in partnering ...
(Date:2/22/2017)... LONDON , Feb. 22, 2017 astic ... new type of antineoplastic drug aiming at functions at ... stepped in to a new stage. Download ... now, there are nearly four million cases of new ... With aging of population, environmental pollution caused by industrialization ...
(Date:2/22/2017)... YORK , Feb. 22, 2017 ... the atherosclerosis partnering deals and agreements entered into ... the full report: http://www.reportlinker.com/p03605675-summary/view-report.html Description ... 2010 report provides understanding and access to partnering ... leading healthcare companies. - Trends in ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... The ... today, as organizations, advocates, and individuals join together to increase recognition about the ... ultimately save lives. , “Today we mark a nationwide movement to raise awareness ...
(Date:2/22/2017)... ... 22, 2017 , ... Becker’s Spine Review, the leading publication ... neurosurgeon Jay Jagannathan, M.D., as a “Spine Surgeon to Know.” http://www.beckersspine.com/spine-leaders/item/35348- . ... Michigan performing minimally invasive back surgery that often results in less post-operative discomfort ...
(Date:2/22/2017)... ... February 22, 2017 , ... Michael J. Hennessy Associates, ... connecting healthcare technology professionals and other key stakeholders with an array of valuable ... on March 1, announced Michael J. Hennessy, Jr., president of MJH Associates. ...
(Date:2/22/2017)... ... 2017 , ... Super-Sod will attend the Athens Home Show with a brand ... shift from Super-Sod’s simple Athens Home Show booth of 2016, this year’s exhibit space ... manager Chris Roquemore constructed furniture from recycled pallet wood at the Super-Sod farm in ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... military veterans who suffer from combat-related PTSD. , Established in 1977, our organization ... Vietnam-era, the challenges of military returning to civilian life were evident and served ...
Breaking Medicine News(10 mins):